Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine cervical IM injection for non-traumatic headache
NCT06937385Phase 3Not yet recruiting
- Sponsor
- North Florida Regional Medical Center
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bupivacaine hydrochloride 0.75% injection in Headache, sponsored by North Florida Regional Medical Center. Planned start May 2025; status: not yet recruiting.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
Headache
Beyond the preview
Go deeper on NCT06937385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937385.